Positive News SentimentPositive NewsNASDAQ:XFOR X4 Pharmaceuticals (XFOR) Stock Forecast, Price & News $1.10 +0.04 (+3.77%) (As of 09/27/2023 ET) Add Compare Share Share Today's Range$1.06▼$1.1150-Day Range$1.03▼$1.8752-Week Range$0.65▼$2.58Volume799,060 shsAverage Volume2.36 million shsMarket Capitalization$180.87 millionP/E RatioN/ADividend YieldN/APrice Target$3.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability X4 Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside218.2% Upside$3.50 Price TargetShort InterestBearish6.62% of Shares Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$147,030 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.78) to ($0.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.39 out of 5 starsMedical Sector259th out of 976 stocksBiological Products, Except Diagnostic Industry39th out of 159 stocks 3.5 Analyst's Opinion Consensus RatingX4 Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.50, X4 Pharmaceuticals has a forecasted upside of 218.2% from its current price of $1.10.Amount of Analyst CoverageX4 Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.62% of the outstanding shares of X4 Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverX4 Pharmaceuticals has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in X4 Pharmaceuticals has recently increased by 5.73%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldX4 Pharmaceuticals does not currently pay a dividend.Dividend GrowthX4 Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreX4 Pharmaceuticals has received a 71.51% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for mental health" and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for X4 Pharmaceuticals is -0.85. Previous Next 3.3 News and Social Media Coverage News SentimentX4 Pharmaceuticals has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for X4 Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 9 people have searched for XFOR on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.MarketBeat Follows4 people have added X4 Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, X4 Pharmaceuticals insiders have sold 390.10% more of their company's stock than they have bought. Specifically, they have bought $30,000.00 in company stock and sold $147,030.00 in company stock.Percentage Held by InsidersOnly 1.08% of the stock of X4 Pharmaceuticals is held by insiders.Percentage Held by Institutions78.50% of the stock of X4 Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for X4 Pharmaceuticals are expected to grow in the coming year, from ($0.78) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of X4 Pharmaceuticals is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of X4 Pharmaceuticals is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioX4 Pharmaceuticals has a P/B Ratio of 1.80. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About X4 Pharmaceuticals (NASDAQ:XFOR) StockX4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.Read More XFOR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XFOR Stock News HeadlinesSeptember 19, 2023 | finance.yahoo.comX4 Pharmaceuticals to Participate in the Cantor Global Healthcare ConferenceSeptember 8, 2023 | markets.businessinsider.comX4 Pharmaceuticals (XFOR) Receives a Buy from B.Riley FinancialSeptember 27, 2023 | Chaikin Analytics (Ad)His system isolated NVIDIA - Here's His Next Buy.Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.September 6, 2023 | finance.yahoo.comX4 Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare ConferenceSeptember 5, 2023 | msn.comX4 submits New Drug Application to FDA for WHIM syndrome drugSeptember 5, 2023 | finance.yahoo.comX4 Pharmaceuticals Announces Submission of New Drug Application (NDA) to U.S. FDA for Mavorixafor in WHIM SyndromeAugust 24, 2023 | msn.comX4: De-Risking By WHIM Indication, Promising Potential For Expansion To Larger MarketAugust 15, 2023 | finance.yahoo.comXFOR: NDA for Mavorixafor in WHIM Syndrome in Early 2H23…September 27, 2023 | Chaikin Analytics (Ad)Buy This Stock for AI Tidal Wave (not NVDA)The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.August 10, 2023 | msn.comX4 Pharmaceuticals GAAP EPS of -$0.33 misses by $0.16August 10, 2023 | finance.yahoo.comX4 Pharmaceuticals Reports Second-Quarter 2023 Financial Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical ProgramAugust 8, 2023 | finance.yahoo.comX4 Pharmaceuticals Announces Industry Veteran Dr. Christophe Arbet-Engels to Join as Chief Medical OfficerAugust 3, 2023 | finance.yahoo.comX4 Pharmaceuticals Closes $115 Million Loan Facility with Hercules CapitalAugust 2, 2023 | finance.yahoo.comX4 Pharmaceuticals to Report Second-Quarter 2023 Financial Results and Host a Conference Call and Webcast on August 10, 2023July 22, 2023 | theglobeandmail.comInstrument Name X4 Pharmaceuticals Inc Instrument Symbol (XFOR-Q)June 14, 2023 | msn.comXFOR: Initiating Coverage of X4 Pharmaceuticals; Investing on More Than Just a WHIM…June 14, 2023 | finance.yahoo.comXFOR: Initiating Coverage of X4 Pharmaceuticals; Investing on More Than Just a WHIM…June 13, 2023 | finance.yahoo.comX4 Pharmaceuticals Expected to Join Russell 3000® IndexMay 25, 2023 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on X4 Pharmaceuticals (XFOR)May 17, 2023 | msn.comStifel Maintains X4 Pharmaceuticals (XFOR) Buy RecommendationMay 17, 2023 | msn.comUnusual Call Option Trade in X4 Pharmaceuticals (XFOR) Worth $24.36KMay 17, 2023 | msn.comX4 Pharma Highlights 'Significant Reduction' Rate In Severity, Duration Of InfectionsMay 16, 2023 | finance.yahoo.comX4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM SyndromeMay 16, 2023 | finance.yahoo.comX4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-MarketMay 5, 2023 | markets.businessinsider.comWhat 5 Analyst Ratings Have To Say About X4 PharmaceuticalsMay 5, 2023 | msn.comHC Wainwright & Co. Reiterates X4 Pharmaceuticals (XFOR) Buy RecommendationMay 4, 2023 | msn.comX4 Pharmaceuticals: Q1 Earnings InsightsSee More Headlines Receive XFOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address XFOR Company Calendar Last Earnings8/10/2023Today9/27/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XFOR CUSIPN/A CIK1501697 Webwww.x4pharma.com Phone(857) 529-8300FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.50 High Stock Price Forecast$5.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+218.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-93,870,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-204.49% Return on Assets-92.04% Debt Debt-to-Equity Ratio0.47 Current Ratio6.64 Quick Ratio6.64 Sales & Book Value Annual Sales$3 million Price / Sales60.29 Cash FlowN/A Price / Cash FlowN/A Book Value$0.61 per share Price / Book1.80Miscellaneous Outstanding Shares164,430,000Free Float162,649,000Market Cap$180.87 million OptionableNot Optionable Beta0.74 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Paula Ragan Ph.D. (Age 53)CEO, Pres & Director Comp: $963.58kMr. Adam S. Mostafa (Age 43)CFO, Treasurer & Corp. Sec. Comp: $699.18kDr. Mary DiBiase Ph.D. (Age 62)Chief Operating Officer Comp: $661.59kDr. Richard Peters M.D. (Age 60)Ph.D., Founder Dr. Renato T. Skerlj Ph.D.FounderDr. Keith T. Flaherty M.D. (Age 52)Founder & Member of Corp. Advisory Board Dr. Arthur Taveras Ph.D. (Age 59)Chief Scientific Officer Dr. Glenn Schulman M.P.H.Pharm. D., Pharm.D., VP of Investor Relations & Corp. CommunicationsDr. Robert David Arbeit (Age 75)Sr. VP of Clinical Devel. and Translational Research Mr. Mark Baldry M.B.A. (Age 59)Chief Commercial Officer More ExecutivesKey CompetitorsAdverum BiotechnologiesNASDAQ:ADVMOrchard TherapeuticsNASDAQ:ORTXInvivydNASDAQ:IVVDERYTECH PharmaNASDAQ:ERYPFusion PharmaceuticalsNASDAQ:FUSNView All CompetitorsInsiders & InstitutionsBarclays PLCBought 87,879 shares on 9/21/2023Ownership: 0.053%Mary DibiaseSold 2,642 sharesTotal: $3,302.50 ($1.25/share)Perceptive Advisors LLCSold 1,000,000 shares on 8/24/2023Ownership: 2.156%California State Teachers Retirement SystemBought 40,956 shares on 8/21/2023Ownership: 0.025%Michael S WyzgaBought 25,000 shares on 8/18/2023Total: $30,000.00 ($1.20/share)View All Insider TransactionsView All Institutional Transactions XFOR Stock - Frequently Asked Questions Should I buy or sell X4 Pharmaceuticals stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for X4 Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" XFOR shares. View XFOR analyst ratings or view top-rated stocks. What is X4 Pharmaceuticals' stock price forecast for 2023? 5 Wall Street analysts have issued 12 month price objectives for X4 Pharmaceuticals' shares. Their XFOR share price forecasts range from $3.00 to $5.00. On average, they predict the company's share price to reach $3.50 in the next year. This suggests a possible upside of 218.2% from the stock's current price. View analysts price targets for XFOR or view top-rated stocks among Wall Street analysts. How have XFOR shares performed in 2023? X4 Pharmaceuticals' stock was trading at $0.9930 on January 1st, 2023. Since then, XFOR stock has increased by 10.8% and is now trading at $1.10. View the best growth stocks for 2023 here. When is X4 Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our XFOR earnings forecast. How were X4 Pharmaceuticals' earnings last quarter? X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) posted its quarterly earnings data on Thursday, August, 10th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.16. During the same quarter in the previous year, the firm posted ($0.60) EPS. What ETF holds X4 Pharmaceuticals' stock ? Simplify Propel Opportunities ETF holds 400,000 shares of XFOR stock, representing 0.72% of its portfolio. What other stocks do shareholders of X4 Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other X4 Pharmaceuticals investors own include Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), AbbVie (ABBV), Flexion Therapeutics (FLXN), Heat Biologics (HTBX) and SCYNEXIS (SCYX). What is X4 Pharmaceuticals' stock symbol? X4 Pharmaceuticals trades on the NASDAQ under the ticker symbol "XFOR." Who are X4 Pharmaceuticals' major shareholders? X4 Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Bain Capital Life Sciences Investors LLC (13.06%), BlackRock Inc. (7.44%), Polar Capital Holdings Plc (4.09%), Stonepine Capital Management LLC (3.77%), Perceptive Advisors LLC (2.16%) and Geode Capital Management LLC (1.92%). Insiders that own company stock include Adam S Mostafa, Adam S Mostafa, Arthur Taveras, Derek M Meisner, Derek M Meisner, Mary Dibiase, Michael S Wyzga, Murray Stewart and Paula Ragan. View institutional ownership trends. How do I buy shares of X4 Pharmaceuticals? Shares of XFOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is X4 Pharmaceuticals' stock price today? One share of XFOR stock can currently be purchased for approximately $1.10. How much money does X4 Pharmaceuticals make? X4 Pharmaceuticals (NASDAQ:XFOR) has a market capitalization of $180.87 million and generates $3 million in revenue each year. The company earns $-93,870,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis. How can I contact X4 Pharmaceuticals? X4 Pharmaceuticals' mailing address is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. The official website for the company is www.x4pharma.com. The company can be reached via phone at (857) 529-8300 or via email at ir@arsanis.com. This page (NASDAQ:XFOR) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding X4 Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.